Source comparison
MK-677 Bodybuilding Oral GH Secretagogue: Comparison
MK-677 (ibutamoren) GHSR-1a agonist (ghrelin mimetic) Oral, once daily +60–90% at 25mg/day ~24 hours Hunger stimulation, mild insulin resistance GHRP-2 GH secretagogue receptor agonist Subcutaneous injection, 2–3×/day +200–300% peak GH (transient) ~30 minutes
This comparison does not assign a generated winner or score.
- MK-677 (ibutamoren)
- GHSR-1a agonist (ghrelin mimetic)
- Oral, once daily
- +60–90% at 25mg/day
- ~24 hours
- Hunger stimulation, mild insulin resistance
- GHRP-2
- GH secretagogue receptor agonist
- Subcutaneous injection, 2–3×/day
- +200–300% peak GH (transient)
- ~30 minutes
- Requires multiple daily injections, appetite surge
- Ipamorelin
- Selective ghrelin receptor agonist
- +150–250% peak GH (transient)
- ~2 hours
- Short half-life, injection site reactions
- CJC-1295 (DAC)
- GHRH analog
- Subcutaneous injection, 1–2×/week
- +200–400% baseline IGF-1
- 6–8 days
- Prolonged GH blunting risk, desensitization
- rhGH (somatropin)
- Exogenous human GH
- Subcutaneous injection, daily
- Dose-dependent (supraphysiologic)
- 3–4 hours
- Shuts down endogenous production, cost, legality
- L-arginine supplements
- Nitric oxide precursor (indirect GH stimulus)
- Oral
- <10% transient increase (if any)
- N/A
- Clinically insignificant for GH secretion